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ABSTRACT 
Background: In intra-abdominal infections, the activity of antimicrobial 
agents against Bacteroides fragilis and phenotypically related organisms, and 
the increasing resistance of these organisms, are of particular importance and 
concern to surgeons: In vitro data suggest that moxifloxacin is more active than 
other quinolones against obligately anaerobic organisms, including Bacteroides 
spp. 
Objective: The aim of this study was to compare the efficacy of moxifloxacin 
monotherapy versus gatifloxacin monotherapy and 2 combination therapies 
(piperacillin-tazobactam nd clindamycin plus gentamicin) in a rat model of 
intra-abdominal sepsis. The end point was marked by the incidence of mortality 
and intra-abdominal bscesses at necropsy 7 days after bacterial challenge. 
Methods: Three different strains of B fragilis with different degrees of resis- 
tance to moxifloxacin (minimum inhibitory concentrations [MICs]: 4, 8, and 
16 pg/mL) were added to the challenge inoculum in 3 separate xperiments. 
Groups of 20 animals were used in each experiment. Group 1 served as saline- 
treated controls; group 2 received moxifloxacin 15 mg QD; group 3 received 
gatifloxacin 25 mg QD; group 4 received piperacillin-tazobactam 93 mg (~83 mg 
of piperacillin) QD; and group 5 received a combination of clindamycin 15 mg 
TID plus gentamicin 2mg TID. All treatments were given intramuscularly. For all 
antimicrobials, dose was based on peak and trough serum drug concentrations 
determined by prior testing, with animal doses adjusted based on the ratio of 
body surface area to body weight, and comparing these doses and levels with 
studies in humans. 
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Results: In all 3 experiments, the mortality rate with moxifloxacin was signif- 
icantly lower or statistically similar compared with antibiotic active compara- 
tots (P _< 0.024). In addition, there were no significant differences in the in- 
cidence of abscess with moxifloxacin versus its comparators or between the 
3 moxifloxacin groups across experiments. The best results for moxifloxacin 
were found in the experiment in which the B fragilis strain with MIC 16 pg/mL 
was added to the inoculum. 
Conclusion: The results of this study in an animal model of intra-abdominal 
sepsis induced by fluoroquinolone-resistant B fragilis suggest that moxifloxacin 
monotherapy performs as well as combination regimens uch as piperacillin- 
tazobactam and clindamycin plus gentamicin, and is as effective as other fluoro- 
quinolones with antianaerobic a tivity, such as gatifloxacin. (Curr Ther Res Clin 
Exp. 2005;66:222-229) Copyright © 2005 Excerpta Medica, Inc. 
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INTRODUCTION 
Previous tudies from the Channing Laboratory, Brigham and Women's Hospital, 
Boston, Massachusetts, 1,2 have shown a variety of antimicrobial agents to be 
effective in preventing both mortality and abscess formation in animal models of 
intra-abdominal sepsis. 3The experimental disease process consists of 2 phases-- 
early acute peritonitis and the development ofabscesses in recipients urviving 
a fecal inoculum. The 2 phases of intra-abdominal sepsis are associated with dis- 
tinctly different bacterial populations. During early acute peritonitis, Escherichia 
coli and other aerobic gram-negative organisms are numerically dominant and 
appear to be the cause of mortality. The second, more chronic stage of the dis- 
ease, abscess formation, requires the presence of obligate anaerobes, uch as 
Bacteroides fragilis. 3 In the rat model of intra-abdominal sepsis, use of antimicro- 
bial agents active against he coliform population has been shown to reduce 
acute mortality, while antimicrobial agents active against obligate anaerobes 
have been shown to reduce the incidence of subsequent abscess formation. 1,2 
In intra-abdominal infections, the activity of an antimicrobial gent against B fra- 
gilis and phenotypically related members of this group is of particular importance. In 
vitro assays uggest that agents lacking documented activity against this organism 
often do not perform well in experimental models imulating intra-abdominal sepsis 
or in humans with serious abdominal infections. 4,5 Other in vitro susceptibility est- 
ing studies have suggested that some strains of B fragilis are moderately resistant to 
moxifloxacin. 6,7However, it is not known whether this resistance was an artifact of 
the testing methodology, orwhether these observations were clinically relevant. 
To determine the in vivo relevance of these in vitro observations, we used a 
rat model of intra-abdominal sepsis to evaluate 3 strains of B fragilis for which 
the minimum inhibitory concentrations (MICs) for moxifloxacin were 4, 8, and 
16 pg/mL. For this group of organisms, the minimum concentration of moxi- 
floxacin that was inhibitory for 90% of all isolates was 0.25 to 2.00 pg/mL. 
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MATERIALS AND METHODS 
Animals 
Male virus antibody-free (VAF) Wistar rats weighing 175 to 200 g were used for 
the study (Charles River Laboratories, Wilmington, Massachusetts). All animals 
were housed in a VAF animal facility and maintained under strict Association for 
Assessment and Accreditation ofLaboratory Animal Care International nd Nation- 
al Institutes of Health guidelines for the care and use of laboratory animals. 8,9 
Inoculum Bacteriology 
The mixed aerobe-anaerobe inoculum from meat-fed rats was prepared as 
described previously. 3 Quantitative and qualitative bacteriology ofthis inoculum 
was performed to ensure the presence of appropriate microbial species. All pro- 
cedures were carried out in an anaerobic hamber to ensure that organisms in 
the inoculum would remain viable and representative of the original cecal mate- 
rial. Enterobacteriaceae were identified using the Vitek system (bioM~rieux SA, 
Durham, North Carolina); anaerobic isolates were identified using the Microbial 
Identification System (Microbial ID, Inc., Newark, Delaware); and aerobic isolates 
were identified using established methods. 1°All isolate counts were recorded as 
log10 colony-forming units per milliliter (CFU/mL) of inoculum. 
Resistant Bacteroides fragilis 
Three clinical strains of B fragilis (Bayer Corporation, West Haven, Con- 
necticut) with different levels of resistance to moxifloxacin were used in the 
experiments. Each strain was grown in brain-heart infusion-supplemented 
broth for 24 to 48 hours, aliquoted, flash-frozen i liquid nitrogen, and stored at 
-80°C. The MIC of moxifloxacin for each strain was confirmed using a micro- 
broth dilution. The MICs for strains 200302049, 200211034, and 200205127 were 
4, 8, and 16 pg/mL, respectively. 
Before each experiment, he aliquots of the test strain were thawed, and 
quantitative counts were performed to document the concentration of viable 
organisms. Viability is maintained at a constant level for up to 2 years after flash 
freezing. The test strains were then added individually to the inoculum, for a 
final concentration f 1 × 108 CFU/mL per animal. 
Implantation of the Inoculum 
Animals were anesthetized with pentobarbital 60 mg/kg and prepared for 
surgical implantation of the inoculum. Their abdomens were shaved, and an 
iodine solution was applied. A 1-cm midline incision was made through the skin 
and anterior abdominal wall, and a gelatin capsule containing 0.5 mL of the 
inoculum containing 10% wt/vol barium sulfate was inserted into the pelvic 
region, as described previously. 3 Although the barium sulfate is nonabscesso- 
genic alone, it acts as a nidus for abscess formation. The incision was closed 
with 3-0 silk suture, and the animals were returned to their cages and monitored 
every 8 hours for the duration of the 7-day experiment. 
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Experimental Design 
The design of each of the 3 experiments was identical. Five groups of 20 ani- 
mals were evaluated in this study. Group 1 served as saline-treated controls; 
group 2 received moxifloxacin 15 mg IM QD; group 3 received gatifloxacin 25 mg 
IM QD; group 4 received a combination solution of piperacillin plus tazobactam 
93 mg IM QD; and group 5 received combination therapy with clindamycin 
15 mg TID plus gentamicin 2 mg TID IM. For all antimicrobials, dose was based 
on peak and trough serum drug concentrations determined by prior testing, with 
animal doses adjusted based on the ratio of body surface area to body weight, 
and comparing these doses and levels with studies in humans. The mean Cma x
values were 6.0, 2.5, 86, and 5.5/6.9 pg/mL in animals receiving moxifloxacin 
(n = 5), gatifloxacin, piperacillin-tazobactam, ndclindamycin plus gentamicin, 
respectively. All Cma ~ values were consistent with those obtained in therapeutic 
use of these agents in humans. 11,12 Treatment was initiated within 2 hours of sur- 
gical implantation ofthe cecal inoculum and was continued for 7 days at intervals 
appropriate for the various antimicrobial gents. Cma ~ values were determined 
using hemolysis inhibition assay 13 1 hour after study drug administration. 
Evaluation of Animals 
Animals were monitored every 8 hours for mortality. Moribund animals were 
euthanized using carbon dioxide (CO2) and were included in the mortality analy- 
sis but not examined for abscess development. Seven days after bacterial chal- 
lenge and initiation of antibiotic treatment, surviving animals were euthanized 
using CO 2, and their abdominal cavities were examined for the presence of intra- 
abdominal abscesses. These examinations were blinded, and abscesses were 
considered to be present if loculated collections of purulent material containing 
polymorphonuclear cells and bacteria were detected) Culture and microscopic 
examination of exudates visually confirmed the presence of abscesses. 
Statistical Analysis 
Mortality and the incidence of abscesses in surviving animals were com- 
pared between the control and treated groups and between the treated groups. 
The program used a 2 x 2 contingency table using the Fisher exact test to pro- 
vide a 1-sided P value (Instat version 3.0, GraphPad Software, Inc., San Diego, 
California). P < 0.05 was considered statistically significant. This study was pow- 
ered to detect a35% difference in mortality and a 50% difference in abscess inci- 
dence versus controls, with 95% confidence. 
RESULTS 
For B fragilis 200302049 (Tables I and lI), 200211034 (Tables III and IV), and 
200205127 (Tables V and VI), all treatment groups had significantly higher mor- 
tality rates compared with untreated controls (all, P < 0.05). In all 3 experi- 
ments, the mortality rate with moxifloxacin was statistically similar compared 
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Table I. Mortality rate and incidence of abscess in rats challenged with an inoculum 
enhanced with Bacteroides fragilis 200302049.* 
Mortality Rate t Incidence of Abscess 
P vs P vs P vs 
Group No. (%) Control No. (%) Control Moxifloxacin 
Saline (control) 10/19 (53) - 9/9 (100) - - 
Moxifloxacin 3/19 (16) <0.020 4/16 (25) <0.001 - 
Gatifloxacin 2/19 (11) <0.007 2/17 (12) <0.001 <0.394 
Piperacillin/tazobactarn 3/19 (16) <0.020 2/16 (13) <0.001 <0.654 
Clindamycin + gentamicin 2/19 (11) <0.007 1/17 (6) <0.001 <0.175 
*Minimum inhibitory concentration, 4 IJg/mL moxifloxacin. 
tNo significant differences versus moxifloxacin were found. 
Table II. Isolates recovered from abdominal abscesses in rats challenged with an 
inoculum enhanced with Bacteroides fragilis 200302049.* 
Run 1 Run 2 Run 3 
Group Isolate MIC Isolate MIC Isolate MIC 
Saline (control) B fragilis <1 B fragilis <1 B fragilis 32 
Moxifloxacin B fragilis 16 B fragilis 16 B fragilis - 
Gatifloxacin B fragilis 16 B fragilis 16 B fragilis - 
Piperacillin/tazobactam B fragilis 8 B fragilis 8 B fragilis 8 
*Minimum inhibitory concentration (MiC), 4 IJg/mL moxifloxacin. 
Table III. Mortality rate and incidence of abscess in rats challenged with an inoculum 
enhanced with Bacteroides fragilis 200211034.* 
Mortality Rate t Incidence of Abscess 
P vs P vs P vs 
Group No. (%) Control No. (%) Control Moxifloxacin 
Saline (control) 11/20 (55) - 9/9 (100) - - 
Moxifloxacin 4/20 (20) <0.025 4/16 (25) <0.187 - 
Gatifloxacin 2/20 (10) <0.003 3/18 (17) <0.063 <0.682 
Piperacillin/tazobactam 3/19 (16) <0.013 3/16 (19) <0.096 1.000 
Clindamycin + gentamicin 2/20 (10) <0.003 2/18 (11) <0.025 <0.388 
*Minimum inhibitory concentration, 8 pg/mL moxifloxacin. 
tNo significant differences versus moxifloxacin were found. 
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Table IV. Isolates recovered from abdominal abscesses in rats challenged with an 
inoculum enhanced with Bacteroides fragilis 200211034.* 
Run 1 Run 2 
Group Isolate MIC Isolate MIC 
Saline (control) B fragilis 4 B fragilis 2 
Moxifloxacin B fragilis 8 B fragilis 16 
Gatifloxacin Bacteroides oralis 32 - - 
Piperacillin/tazobactam Bacteroides spp 8 B fragilis 16 
Clindamycin + gentamicin B fragilis 8 - - 
*Minimum inhibitory concentration (MIC), 8 pg/mL moxifloxacin. 
Table V. Mortality rate and incidence of abscess in rats challenged with an inoculum 
enhanced with Bacteroides fragilis 200205127.* 
Mortality Rate t Incidence of Abscess 
P vs P vs P vs 
Group No. (%) Control No. (%) Control Moxifloxacin 
Saline (control) 10/19 (53) - 9/9 (100) - - 
Moxifloxacin 0/20 (0) <0.001 2/19 (11) <0.001 - 
Gatifloxacin 0/20 (0) <0.001 5/20 (25) <0.001 <0.408 
Piperacillin/tazobactam 0/19 (0) <0.001 2/19 (11 ) <0.001 <1.397 
Clindamycin + gentamicin 0/20 (0) <0.001 2/18 (11) <0.001 1.000 
*Minimum inhibitory concentration, 16 Mg/mL moxifloxacin. 
tNo significant differences versus moxifloxacin were found. 
Table VI. Isolates recovered from abdominal abscesses in rats challenged with an 
inoculum enhanced with Bacteroidesfragilis 200205127.* 
Run 1 Run 2 Run 3 
Group Isolate MIC Isolate MIC Isolate MIC 
Saline (control) B fragilis 8 B fragilis 8 - - 
Moxifloxacin Bacteroides spp 2 B fragilis 16 B fragilis 16 
Gatifloxacin Bacteroides spp 16 B fragilis 8 - - 
Piperacillin/tazobactam B fragilis 8 B fragilis 8 - - 
Clindamycin + gentamicin B fragilis 16 B fragilis 8 - - 
*Minimum inhibitory concentration (MIC), 16 IJg/mL moxifloxacin. 
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with antibiotic active comparators. When the incidence of abscess at necropsy 
was compared between all of the treatment groups, the rates were statistically 
similar (Tables I, III, and V). Analysis of abscess cultures indicated that the 
organisms recovered were consistent with inoculum contents and did not con- 
flict with the results of the analysis of organisms and their susceptibility data 
(Tables II, IV, and VI). 
DISCUSSION 
Previous in vitro susceptibility esting studies have suggested that some strains 
of B fragilis are moderately resistant to moxifioxacin, 6 but it was not known 
whether these findings were an artifact of the testing methodology or whether 
these observations were clinically relevant. To determine the relevance of these 
in vitro observations in vivo, we used a rat model of intra-abdominal sepsis to 
evaluate 3 strains of B fragilis for which the MICs for moxifloxacin ranged from 
4 to 16 pg/mL. In all 3 experiments, the mortality rate in the moxifloxacin group 
was statistically similar to or lower than that in the groups receiving compar- 
ator antibiotics (gatifloxacin, piperacillin/tazobactam, nd clindamycin plus 
gentamicin). In addition, there were no statistically significant differences in 
abscess rates with moxifloxacin either compared with the other antibiotics test- 
ed or between experiments for moxifloxacin. Indeed, the best results for moxi- 
floxacin were found in the experiment in which the inoculum contained the 
B fragilis strain for which the MIC was 16 pg/mL. 
CONCLUSION 
In this study in a rat model of intra-abdominal sepsis, moxifloxacin used as mono- 
therapy performed as well as the combination regimens piperacillin-tazobactam 
and clindamycin plus gentamicin, and was as effective as gatifloxacin, another 
fluoroquinolone with antianaerobic a tivity. 
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